Heroin

PAINWeekEnd in Sacramento, CA, Offers CE/CME Education to Meet the Challenges of Opioid Prescribing Regulation

Retrieved on: 
Monday, November 11, 2019
RTT, Opioids, Morphine, Psychoactive drugs, Drugs, Morphinans, Heroin, Opioid epidemic in the United States

In 2018, the California legislature passed new laws intended to address the crisis of opioid abuse in the state.

Key Points: 
  • In 2018, the California legislature passed new laws intended to address the crisis of opioid abuse in the state.
  • Additional regulatory measures are scheduled to go into effect over the next 2 years.
  • For more information about this or other regional conferences, and to register for $129, go to the PAINWeekEnd website.
  • About Global Education Group:
    Global Education Group focuses on producing partnership-based CME for healthcare practitioners.

Families Across the Nation Challenged to Help Knock Out Opioid Abuse

Retrieved on: 
Thursday, November 7, 2019
Psychoactive drugs, RTT, Morphine, Substance abuse, Medical emergencies, Opioids, Drugs, Drug overdose, Heroin

"The American Medicine Chest Challenge's 5-step challenge can help save the lives of our children," said Angelo M. Valente, CEO of AMCC.

Key Points: 
  • "The American Medicine Chest Challenge's 5-step challenge can help save the lives of our children," said Angelo M. Valente, CEO of AMCC.
  • "We know that many teens who misuse opioids get them from the medicine cabinets of their friends and families, so it is crucial for people to safeguard medicine within their homes.
  • Research from the National Institute on Drug Abuse (NIH) reveals that approximately 80 percent of heroin users have a history of prescription drug misuse.
  • In 2018, 47,590 people in the United States died from an opioid overdose, an additional 14,000 deaths fromthe year prior, according to The National Center for Health Statistics.

BioDelivery Sciences to Present at the 10th Annual Jefferies Global Healthcare Conference in London

Retrieved on: 
Thursday, November 7, 2019
Opioids, RTT, Medicine, Psychoactive drugs, Morphine, Pain, Morphinans, Cancer pain, Substance dependence, Chronic pain, Heroin

A replay of the presentation will be archived on the Company's website and made available for 60 days.

Key Points: 
  • A replay of the presentation will be archived on the Company's website and made available for 60 days.
  • BioDelivery Sciences International, Inc.(NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
  • BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
  • BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, opioid dependence, and opioid-induced constipation.

WCF Mutual Insurance and Mitchell Release Study on the Impact of Opioid Guidelines-Based Program on Opioid Prescribing in Utah, Showing a Reduction of 13,000 Opioid Pills Dispensed to Injured Workers

Retrieved on: 
Wednesday, November 6, 2019
Professional services, Health, Insurance, Other Health, Human resources, Pharmaceutical, Psychoactive drugs, Morphine, RTT, Opioids, Drugs, Euphoriants, Morphinans, Heroin, Opioid use disorder, Opioid epidemic in the United States

The study examined the impact of implementing an evidence-based, guidelines-based program on opioid use and abuse in Utah.

Key Points: 
  • The study examined the impact of implementing an evidence-based, guidelines-based program on opioid use and abuse in Utah.
  • Among the factors studied were the number of opioid pills prescribed, the time length of prescriptions, and outcomes from the changes implemented by WCF and Mitchell.
  • This equates to a 56.4 percent reduction of opioid pills dispensed versus prescribed, a total of more than 13,000 opioid pills.
  • To better serve multistate customers, WCF acquired WCF National Insurance Company in 1998 to write workers' compensation outside Utah.

PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Health, Science, Other Science, Research, Morphine, Psychoactive drugs, Health, Drugs, RTT, National Institutes of Health, Nursing research, Opioid, National Institute of Neurological Disorders and Stroke, Addiction, Heroin, the HEAL Initiative, the PSPP Program, PsychoGenics

This project has been funded in whole or in part with Federal funds from NINDS, NIH, Department of Health and Human Services, under Contract Number 75N95019D00026.

Key Points: 
  • This project has been funded in whole or in part with Federal funds from NINDS, NIH, Department of Health and Human Services, under Contract Number 75N95019D00026.
  • PSPP is part of the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative.
  • The HEAL Initiative is a trans-NIH research effort focused on improving prevention and treatment for opioid misuse and addiction and enhancing pain management.
  • It is an efficient, rigorous, one-stop resource for preclinical screening of potential pain therapeutic agents.

Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe

Retrieved on: 
Tuesday, November 5, 2019
Opioids, Organic compounds, Chemical compounds, RTT, Morphinans, Tertiary alcohols, Morphine, Opioid antagonists, Naloxone, Drug overdose, Heroin, Opioid use disorder

Adamis intends to make an announcement relating to FDA action concerning the NDA after it receives a notice of action or similar communication from the agency.

Key Points: 
  • Adamis intends to make an announcement relating to FDA action concerning the NDA after it receives a notice of action or similar communication from the agency.
  • ZIMHI is a high-dose naloxone injection product candidate intended for the treatment of opioid overdose.
  • Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose.
  • Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose.

Cara Therapeutics Announces Presentations at Kidney Week 2019

Retrieved on: 
Friday, November 1, 2019
Drugs, Chemical compounds, Morphine, Opioid receptors, Morphinans, Opioids, Difelikefalin, Heroin, κ-opioid receptor

STAMFORD, Conn., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced a late-breaking oral presentation and two posters on KORSUVA (CR845/difelikefalin) Injection will be presented at Kidney Week 2019, the American Society of Nephrologys Annual Meeting, to be held November 5-10, 2019, in Washington, DC.

Key Points: 
  • STAMFORD, Conn., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced a late-breaking oral presentation and two posters on KORSUVA (CR845/difelikefalin) Injection will be presented at Kidney Week 2019, the American Society of Nephrologys Annual Meeting, to be held November 5-10, 2019, in Washington, DC.
  • KORSUVA Injection is Caras first-in-class drug candidate designed to target kappa opioid receptors in the bodys peripheral nervous system, as well as certain immune cells.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Global $17.29 Billion Subcutaneous Drug Delivery Devices Markets, 2018 & 2019-2027

Retrieved on: 
Thursday, October 31, 2019
Pharmacology, Health sciences, Health, Drug paraphernalia, Medical equipment, Syringe, Routes of administration, Dosage forms, Transdermal patch, Heroin

DUBLIN, Oct. 31, 2019 /PRNewswire/ -- The "Subcutaneous Drug Delivery Devices Market to 2027 - Global Analysis and Forecasts by Technology; Syringe Type; Distribution Channel and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 31, 2019 /PRNewswire/ -- The "Subcutaneous Drug Delivery Devices Market to 2027 - Global Analysis and Forecasts by Technology; Syringe Type; Distribution Channel and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global subcutaneous drug delivery devices market is expected to reach US$ 17,290.47 Mn in 2027 from US$ 9,243.80 in 2018.
  • The global subcutaneous drug delivery devices market, based on the technology was segmented into syringes, pens, patches and others.
  • However, the patches segmented is anticipated to witness fastest growth in the subcutaneous drug delivery devices market, based on technology.

Subcutaneous Drug Delivery Devices Market to 2027 - Global Analysis and Forecasts by Technology, Syringe Type, Distribution Channel and Geography - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 31, 2019
Pharmaceutical, Health, Medical devices, Pharmacology, Health sciences, Health, Drug paraphernalia, Medical equipment, Syringe, Routes of administration, Dosage forms, Heroin, Transdermal patch

The "Subcutaneous Drug Delivery Devices Market to 2027 - Global Analysis and Forecasts by Technology; Syringe Type; Distribution Channel and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Subcutaneous Drug Delivery Devices Market to 2027 - Global Analysis and Forecasts by Technology; Syringe Type; Distribution Channel and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global subcutaneous drug delivery devices market is expected to reach US$ 17,290.47 Mn in 2027 from US$ 9,243.80 in 2018.
  • The global subcutaneous drug delivery devices market, based on the technology was segmented into syringes, pens, patches and others.
  • However, the patches segmented is anticipated to witness fastest growth in the subcutaneous drug delivery devices market, based on technology.

SVS - Patients with artery disease are taking more painkillers, but reasons are complex

Retrieved on: 
Wednesday, October 30, 2019
Drugs, RTT, Morphine, Drug rehabilitation, Opioids, Euphoriants, Heroin, Opioid use disorder, Opioid rotation

Researchers discovered that some patients who had a procedure to improve pain from poor circulation actually increased their use of opioids after treatment.

Key Points: 
  • Researchers discovered that some patients who had a procedure to improve pain from poor circulation actually increased their use of opioids after treatment.
  • For patients without CLI, high opioid use increased from 22.7% before treatment to 25.9% after treatment and from 30.8% before treatment to 37.1% after treatment for patients with CLI.
  • The study found that high-opioid use patients were more likely to have back and neck pain, be smokers and/or have depression.
  • High opioid use was defined in the study as patients who were prescribed two or more opioid prescriptions in a year.